Details of the Drug

General Information of Drug (ID: DMUPFLI)

Drug Name
Deutetrabenazine
Synonyms Dutetrabenazine; Austedo; SD809; SD-809; SD 809; 1392826-25-3; Deutetrabenazine [USAN:INN]
Indication
Disease Entry ICD 11 Status REF
Huntington disease 8A01.10 Approved [1]
Tardive dyskinesia 8A02.10 Approved [2]
Affected Organisms
Humans and other mammals
ATC Code
N07XX16: Deutetrabenazine
N07XX: Other nervous system drugs
N07X: OTHER NERVOUS SYSTEM DRUGS
N07: OTHER NERVOUS SYSTEM DRUGS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 323.5
Logarithm of the Partition Coefficient (xlogp) 2.9
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Clearance
The clearance of drug is 47 L/h []
Elimination
In healthy subjects, about 75% to 86% of the deutetrabenazine dose was excreted in the urine, and fecal recovery accounted for 8% to 11% of the dose []
Half-life
The concentration or amount of drug in body reduced by one-half in 9 - 10 hours []
Metabolism
The drug is metabolized via the hepatic []
Vd
The volume of distribution (Vd) of drug is 500 L []
Chemical Identifiers
Formula
C19H27NO3
IUPAC Name
(3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
Canonical SMILES
[2H]C([2H])([2H])OC1=C(C=C2[C@H]3CC(=O)[C@@H](CN3CCC2=C1)CC(C)C)OC([2H])([2H])[2H]
InChI
InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1/i3D3,4D3
InChIKey
MKJIEFSOBYUXJB-VFJJUKLQSA-N
Cross-matching ID
PubChem CID
73437646
CAS Number
1392826-25-3
UNII
P341G6W9NB
DrugBank ID
DB12161
TTD ID
D0E7ZU
VARIDT ID
DR01127
INTEDE ID
DR0445
ACDINA ID
D00184
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Synaptic vesicle amine transporter (SLC18A2) TTNZRI3 VMAT2_HUMAN Modulator [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [4]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Huntington disease
ICD Disease Classification 8A01.10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Synaptic vesicle amine transporter (SLC18A2) DTT SLC18A2 2.69E-02 -0.04 -0.11
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Deutetrabenazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Deutetrabenazine and Ivosidenib. Acute myeloid leukaemia [2A60] [6]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Deutetrabenazine and Oliceridine. Acute pain [MG31] [7]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Deutetrabenazine and Levalbuterol. Asthma [CA23] [8]
Givosiran DM5PFIJ Moderate Decreased metabolism of Deutetrabenazine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [9]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Deutetrabenazine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [10]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Deutetrabenazine and Selpercatinib. Lung cancer [2C25] [11]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Deutetrabenazine and Siponimod. Multiple sclerosis [8A40] [12]
Ozanimod DMT6AM2 Major Additive hypertensive effects by the combination of Deutetrabenazine and Ozanimod. Multiple sclerosis [8A40] [7]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Deutetrabenazine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [11]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Deutetrabenazine and Rucaparib. Ovarian cancer [2C73] [7]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Deutetrabenazine and Triclabendazole. Parasitic worm infestation [1F90] [7]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Deutetrabenazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [13]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Deutetrabenazine and Lefamulin. Pneumonia [CA40] [14]
⏷ Show the Full List of 13 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylated hydroxytoluene E00336 31404 Antioxidant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Deutetrabenazine 12 mg tablet 12 mg Oral Tablet Oral
Deutetrabenazine 6 mg tablet 6 mg Oral Tablet Oral
Deutetrabenazine 9 mg tablet 9 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
5 FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
6 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
7 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
8 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
9 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
10 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Cerner Multum, Inc. "Australian Product Information.".
13 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
14 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.